Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

Next Previous
X
Search
Trial Profile

A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenacapavir (Primary) ; Lenacapavir (Primary) ; Teropavimab (Primary) ; Zinlirvimab (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Proof of concept
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 06 Mar 2024 Results (n=11) assessing safety & efficacy of LEN+TAB+ZAB for maintenance of VS in a cohort of participants who met viral sensitivity criteria to either TAB or ZAB, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 05 Mar 2024 According to a Gilead Sciences media release, data from this study were published in The Lancet HIV.
    • 05 Mar 2024 Results published in the Gilead Sciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top